공시 • Apr 02
NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filing On 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Jun 08
NYSE American Accepts NovaBay Pharmaceuticals Plan of Compliance NovaBay Pharmaceuticals, Inc. (the Company") announced that the NYSE American LLC (NYSE American") has accepted the Company's plan to regain compliance with NYSE American's continued listing standards. I'm pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we're now able to focus solely on our core competency in eyecare," said Justin Hall, CEO of NovaBay. Unshackled by past burdens, we are positioned for growth in the large U.S. eyecare market with our established, high-quality Avenova -branded products, effective and cost-efficient digital marketing programs, and loyal customer base. This is an exciting and transformative time for the Company." The NYSE American has reviewed NovaBay's compliance plan and information submitted on May 8, 2024 and determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance by October 18, 2025. During this time, the Company will be subject to quarterly monitoring for compliance with the plan. If the Company does not regain compliance with NYSE American's listing standards by October 18, 2025, or if the Company does not make sufficient progress consistent with its plan, then the NYSE American may initiate delisting proceedings at that time. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide, requiring a listed company to have a certain amount of stockholders' equity. The Company's receipt of such notification from NYSE American does not affect the Company's business operations or its reporting requirements with the U.S. Securities and Exchange Commission. 공시 • May 30
NovaBay Pharmaceuticals Provides Non-Compliance Update NovaBay Pharmaceuticals, Inc. (the Company") announced that stockholders approved a reverse stock split and authorized the Company's Board of Directors to determine the specific split ratio and effective date. We thank stockholders for their support in approving all proposals during our annual meeting," said Justin Hall, NovaBay's CEO. The approval of these proposals allows us to move forward with several strategic initiatives meant to help us regain compliance with NYSE American's continued listing standards and grow our business. We believe the anticipated increased market price resulting from the reverse split will improve the marketability and liquidity of our stock and could encourage additional interest and trading." The Company's Board of Directors has authorized a 1-for-35 reverse stock split of all outstanding shares of common stock of the Company. The Company anticipates that the 1-for-35 reverse stock split will be effective as of 4:15 p.m. New York City time on May 30, 2024, and that the Company's common stock will begin trading on a split-adjusted basis on May 31, 2024. The Company expects that the reverse stock split will increase the per-share price of its common stock, which the Company believes will enable it to comply with the NYSE American's continued-listing requirement relating to the price of its common stock. The Company's trading symbol of NBY" will not change as a result of the reverse stock split; however, a new CUSIP number has been assigned: 66987P 409. The Company also announced that on May 28, 2024 it received notice from the NYSE American that it is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide requiring stockholders' equity of $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of the three most recent fiscal years. In a press release dated April 19, 2024, the Company announced notification by the NYSE American on April 18, 2024 that it was not in compliance with the minimum stockholders' equity requirement of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. On May 8, 2024, the Company submitted its plan to regain compliance to NYSE American. The Company is subject to the requirements in the April and May notice and if the Company is not in compliance with all of the stockholders' equity standards by October 18, 2025 or does not make substantial progress consistent with its compliance plan, then the NYSE American staff will initiate delisting proceedings, as appropriate. The Additional Deficiency Letter has no immediate effect on the listing or trading of the Company's common stock, par value $0.01 (Common Stock"), and the Company's common stock will continue to trade on the NYSE American under the symbol NBY" with a below compliance" indicator appended to the Company's ticker symbol (with the added designation of .BC") during the period the Company is not in compliance with the NYSE American's continued listing standards. The Company's receipt of the Additional Deficiency Letter does not affect the Company's business operations or its reporting requirements with the SEC. 공시 • Oct 10
NovaBay Pharmaceuticals Receives NYSE American Notice Regarding Low Share Price NovaBay Pharmaceuticals, Inc. announced that on October 3, 2022 it received a notice from the NYSE American LLC that the Company’s common stock has been selling for a low price per share for a substantial period of time. As a result, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company must effect a reverse stock split of its common stock or otherwise demonstrate sustained price improvement within a reasonable period of time, which the NYSE American has determined to be no later than April 3, 2023, in order to continue its listing on the NYSE American. The Company intends to take steps to improve its stock price, which include the filing of a definitive proxy statement with the Securities and Exchange Commission (‘SEC’) to hold a Special Meeting of Stockholders (the ‘Special Meeting’) on November 10, 2022 seeking stockholder authorization of a reverse stock split at a ratio of between 1-for-10 and 1-for-35. The notice from the NYSE American has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on the NYSE American. The Company expects that the reverse stock split, if approved by stockholders at the Special Meeting and effected, will increase the market price of its common stock, which the Company believes will enable it to satisfy the continued listing requirements of the NYSE American for the foreseeable future. In addition, the reverse stock split may improve the marketability and liquidity of its common stock, and appeal to a broader range of investors. Further, due to the number of shares of common stock underlying the securities issued, or to be issued, in connection with two financing transactions entered into on September 9, 2022, the NYSE American rules require the Company to seek stockholder approval prior to the issuance of those underlying shares. The additional capital from these transactions is expected to support implementation of the Company’s growth strategies. ‘Like other small publicly traded companies, NovaBay has faced challenging market conditions during 2022, prompting us to seek stockholder approval to effect a reverse stock split and to raise additional capital to fund our business strategy,’ said Justin Hall, NovaBay Chief Executive Officer. ‘That said, we are optimistic about our prospects for continued sales growth. We are building on established brands in the large and growing eyecare, skincare and wound care markets with differentiated products that are scientifically developed and clinically proven. We are executing on a commercial strategy featuring multiple product launches while leveraging new market opportunities and broadening distribution of our current products. Given the timing of implementing our growth initiatives and other anticipated favorable developments, we continue to expect topline growth through 2022 and into 2023.’ The definitive proxy statement was filed with the SEC on September 30, 2022 and is available here. All NovaBay stockholders of record at the close of business on the record date, September 13, 2022, are entitled to vote their shares of Company common stock at the Special Meeting. Every stockholder’s vote is important, regardless of the number of shares held, and the Company requests the prompt submission of votes.